Please use this identifier to cite or link to this item: https://observatorio.fm.usp.br/handle/OPI/5261
Full metadata record
DC FieldValueLanguage
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP-
dc.contributor.authorSOUZA, Dinoelia Rosa-
dc.contributor.authorGOMIDES, Ricardo Saraceni-
dc.contributor.authorCOSTA, Luiz Augusto Riani-
dc.contributor.authorFERNANDES, Joao Ricardo Cordeiro-
dc.contributor.authorORTEGA, Katia Coelho-
dc.contributor.authorMION JR., Decio-
dc.contributor.authorTINUCCI, Tais-
dc.contributor.authorFORJAZ, Claudia Lucia de Moraes-
dc.date.accessioned2014-04-25T22:04:57Z-
dc.date.available2014-04-25T22:04:57Z-
dc.date.issued2013-
dc.identifier.citationREVISTA BRASILEIRA DE MEDICINA DO ESPORTE, v.19, n.5, p.339-342, 2013-
dc.identifier.issn1517-8692-
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/5261-
dc.description.abstractIntroduction: Aerobic exercise is recommended for the treatment of hypertension. Its intensity can be prescribed based on the percentage of maximum heart rate (% MHR) or peak oxygen consumption (VO2peak%) in which the ventilatory thresholds (VT) are achieved. However, some hypertensive patients who begin aerobic training may be receiving beta-blockers, which can influence these parameters. Objective: To investigate the effects of atenolol on VT of sedentary hypertensive patients. Methods: Nine volunteers performed two cardiopulmonary exercise tests until exhaustion after 4 weeks of treatment with atenolol (25 mg orally twice daily) and with placebo, administered in a fixed order and in a blinded manner. During the tests, heart rate (HR), blood pressure (BP), VO2 at rest, anaerobic threshold (AT), respiratory compensation point (RCP) and peak effort were analyzed. Results: VO2 increased progressively throughout the exercise and the values were similar for both treatments. Systolic blood pressure and heart rate also increased progressively during the exercise, but their absolute values were significantly lower with atenolol. However, the increase in systolic BP and HR during exercise was similar in both treatments. Thus, the % of MHR and % VO2peak at which LA and PCR were achieved were not different between placebo and atenolol. Conclusion: Atenolol, at a dosage of 50mg/day, did not affect the % of VO2peak and % of MHR corresponding to the VTs, which confirms that prescription of training intensity based on these percentages is adequate to hypertensive patients receiving beta-blockers.-
dc.description.abstractIntrodução: O exercício aeróbio é recomendado para o tratamento da hipertensão. Sua intensidade pode ser prescrita com base na porcentagem da frequência cardíaca máxima (%FCmáx) ou no consumo pico de oxigênio (%VO2pico) em que os limiares ventilatórios (LV) são alcançados. Entretanto, alguns hipertensos que iniciam o treinamento podem estar tomando betabloqueadores, o que pode influenciar esses parâmetros. Objetivo: Verificar os efeitos do atenolol sobre os LV de hipertensos sedentários. Métodos: Nove voluntários realizaram dois testes ergoespirométricos máximos após quatro semanas de tratamento com atenolol (25 mgadministrado por via oral duas vezes por dia) e com placebo, administrados em ordem fixa e de forma cega. Durante os testes, a frequência cardíaca (FC), a pressão arterial (PA) e o VO2 no repouso, limiar anaeróbio (LA), ponto de compensação respiratória (PCR) e pico do esforço foram analisados. Resultados: O VO2 aumentou progressivamente no exercício e seus valores foram semelhantes nos dois tratamentos. A PA sistólica e a FC também aumentaram no exercício, mas seus valores absolutos foram significativamente menores com o atenolol. Porém, o aumento da PA sistólica e da FC no exercício foi semelhante com os dois tratamentos. Assim, o percentual da FCmáx e o percentual do VO2pico em que LA e PCR foram alcançados não diferiram entre o placebo e o atenolol. Conclusão: O atenolol na dosagem de 50 mg/dia não afetou o percentual do VO2pico e da FCmáx em que os LV são atingidos, o que confirma que a prescrição de intensidade de treinamento com base nessas porcentagens pode ser mantida em hipertensos que recebem betabloqueadores.-
dc.description.sponsorshipFAPESP-
dc.language.isoeng-
dc.language.isopor-
dc.publisherSOC BRASILEIRA MED ESPORTE-
dc.relation.ispartofRevista Brasileira de Medicina do Esporte-
dc.rightsopenAccess-
dc.subjectbeta-adrenergic blockers-
dc.subjectanaerobic threshold-
dc.subjecthypertension-
dc.subjectbetabloqueador-
dc.subjectlimiar anaeróbio-
dc.subjecthipertensão arterial sistêmica-
dc.subject.otheradrenoceptor blockade-
dc.subject.otherexercise performance-
dc.subject.otheradrenergic-blockade-
dc.subject.othersubmaximal exercise-
dc.subject.otherblood-pressure-
dc.titleBetabloqueio com atenolol não reduz potência aeróbia nem muda limiares ventilatórios em hipertensos sedentários-
dc.title.alternativeATENOLOL BETA-BLOCK DOES NOT DECREASE AEROBIC POWER OR ALTER VENTILATORY THRESHOLDS IN SEDENTARY HYPERTENSIVE SUBJECTS-
dc.typearticle-
dc.rights.holderCopyright SOC BRASILEIRA MED ESPORTE-
dc.identifier.doi10.1590/S1517-86922013000500008-
dc.subject.wosPhysiology-
dc.subject.wosSport Sciences-
dc.type.categoryoriginal article-
dc.type.versionpublishedVersion-
hcfmusp.author.externalSOUZA, Dinoelia Rosa:Univ Sao Paulo, Exercise Hemodynam Lab, Sch Phys Educ & Sport, BR-05508 Sao Paulo, Brazil-
hcfmusp.author.externalGOMIDES, Ricardo Saraceni:Univ Sao Paulo, Exercise Hemodynam Lab, Sch Phys Educ & Sport, BR-05508 Sao Paulo, Brazil-
hcfmusp.author.externalCOSTA, Luiz Augusto Riani:Univ Sao Paulo, Exercise Hemodynam Lab, Sch Phys Educ & Sport, BR-05508 Sao Paulo, Brazil-
hcfmusp.author.externalTINUCCI, Tais:Univ Sao Paulo, Exercise Hemodynam Lab, Sch Phys Educ & Sport, BR-05508 Sao Paulo, Brazil-
hcfmusp.author.externalFORJAZ, Claudia Lucia de Moraes:Univ Sao Paulo, Exercise Hemodynam Lab, Sch Phys Educ & Sport, BR-05508 Sao Paulo, Brazil-
hcfmusp.description.beginpage339-
hcfmusp.description.endpage342-
hcfmusp.description.issue5-
hcfmusp.description.volume19-
hcfmusp.origemWOS-
hcfmusp.origem.id2-s2.0-84890261170-
hcfmusp.origem.idWOS:000328703800008-
hcfmusp.origem.idSCIELO:S1517-86922013000500008-
hcfmusp.publisher.citySAO PAULO SP-
hcfmusp.publisher.countryBRAZIL-
hcfmusp.relation.referenceAmerican College of Sports Medicine, 2010, ACSMS GUID EX TEST P-
hcfmusp.relation.referenceBrunton LL, 2007, GOODMAN GILMAN BASES-
hcfmusp.relation.referenceCHICK TW, 1988, MED SCI SPORT EXER, V20, P447-
hcfmusp.relation.referenceCole CR, 2000, ANN INTERN MED, V132, P552-
hcfmusp.relation.referenceEPSTEIN SE, 1965, J CLIN INVEST, V44, P1745, DOI 10.1172/JCI105282-
hcfmusp.relation.referenceEynon N, 2008, J CARDIOPULM REHABIL, V28, P189, DOI 10.1097/01.HCR.0000320070.81470.75-
hcfmusp.relation.referenceFagard RH, 2007, EUR J CARDIOV PREV R, V14, P12, DOI 10.1097/HJR.0b013e3280128bbb-
hcfmusp.relation.referenceGORDON NF, 1985, BRIT HEART J, V54, P96-
hcfmusp.relation.referenceMCLEOD AA, 1985, BRIT J CLIN PHARMACO, V19, P13-
hcfmusp.relation.referenceMier CM, 1997, J APPL PHYSIOL, V83, P1660-
hcfmusp.relation.referenceNegrao CE, 2010, CARDIOLOGIA EXERCICI-
hcfmusp.relation.referencePEARSON SB, 1979, BRIT J CLIN PHARMACO, V8, P143-
hcfmusp.relation.referencePescatello LS, 2004, MED SCI SPORT EXER, V36, P533, DOI 10.1249/01.MSS.0000115224.88514.3A-
hcfmusp.relation.referenceRASMUSSEN PH, 1985, CHEST, V87, P743, DOI 10.1378/chest.87.6.743-
hcfmusp.relation.referenceREYBROUCK T, 1977, J APPL PHYSIOL, V42, P133-
hcfmusp.relation.referenceSociedade Brasileira de Hipertensao, 2010, REV BRAS HIPERTENS, V13, P1-
hcfmusp.relation.referenceTask Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology, 1996, CIRCULATION, V93, P1043-
hcfmusp.relation.referenceTESCH PA, 1985, SPORTS MED, V2, P389, DOI 10.2165/00007256-198502060-00002-
hcfmusp.relation.referenceThompson PD, 1989, AM J MED, V23, P104-
hcfmusp.relation.referenceVANBAAK MA, 1988, SPORTS MED, V5, P209, DOI 10.2165/00007256-198805040-00002-
hcfmusp.relation.referenceVANBAAK MA, 1991, BRIT J CLIN PHARMACO, V32, P723-
hcfmusp.relation.referenceVanzelli AS, 2005, REV SOC CARDIOL E, V15, P10-
hcfmusp.relation.referenceVlak MHM, 2012, J NEUROL, V259, P1298, DOI 10.1007/s00415-011-6341-1-
hcfmusp.relation.referenceWasserman K., 1994, PRINCIPLES EXERCISE-
dc.description.indexWoS-
dc.identifier.eissn1806-9940-
hcfmusp.remissive.sponsorshipFAPESP-
hcfmusp.citation.scopus0-
hcfmusp.scopus.lastupdate2024-02-23-
Appears in Collections:

Artigos e Materiais de Revistas Científicas - HC/ICHC
Instituto Central - HC/ICHC

Artigos e Materiais de Revistas Científicas - HC/InCor
Instituto do Coração - HC/InCor


Files in This Item:
File Description SizeFormat 
art_FERNANDES_ATENOLOL_BETA_BLOCK_DOES_NOT_DECREASE_AEROBIC_POWER_2013_eng.PDFpublishedVersion (English)127.83 kBAdobe PDFThumbnail
View/Open
art_FERNANDES_ATENOLOL_BETA_BLOCK_DOES_NOT_DECREASE_AEROBIC_POWER_2013_por.PDFpublishedVersion (Portuguese)109.57 kBAdobe PDFThumbnail
View/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.